Resideo Technologies, Inc. REZI 深 滬
等待開盤 12-13 09:30:00 美东时间
36.19
-0.060
-0.17%
華盛通- 最 高36.495
- 今 開36.24
- 成交量 248.11万股
- 最 低 35.3601
- 昨 收 36.25
- 總市值 54.29亿
- 52周最高 45.29
- 市盈率 靜 59.26
- 換手率 1.65%
- 52周最低 14.18
- 委 比 -94.65%
- 總股本 1.50亿
- 歷史最高 45.29
- 量 比 1.60
- 振 幅 3.13%
- 歷史最低 3.72
- 每 手 1
- 風險率 8.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Resideo Sells Grid Services Demand Response Business To Alarm.com's EnergyHub To Refocus On Core Residential Controls And Sensing Products; The Terms Of The Transaction Were Not Disclosed
Resideo Technologies, Inc. (NYSE:REZI), a leading global manufacturer, developer, and distributor of technology-driven sensing and controls products and solutions for residential end-markets, today announced that
12-03 05:12
How Do Investors Really Feel About Resideo Technologies Inc?
Resideo Technologies Inc's (NYSE:REZI) short interest as a percent of float has...
11-21 21:00
美股盘后 | Resideo Technologies跌20.24%
Resideo Technologies将于11月5日盘后发布2025年第三季度财报，分析师预期每股收益0.67美元，营收18.8亿美元。
11-06 07:29
美股盘后 | Resideo Technologies跌18.17%
Resideo Technologies将于11月5日盘后公布季度财报，市场预期每股收益0.67美元，营收18.8亿美元，这份2025年财报的业绩表现备受投资者关注。
11-06 06:06
Resideo Technologies shares are trading lower after the company reported mixed Q3 financial results and issued Q4 guidance below estimates. Also, Rediso Technologies cut its FY25 guidance below estimates
Resideo Technologies shares are trading lower after the company reported mixed ...
11-06 06:04
美股盘后 | Resideo Technologies跌13.31%
Resideo Technologies将于11月5日发布第三季度财报，市场预期每股收益0.67美元，营收18.8亿美元。分析师对公司业绩持积极态度，认为将实现盈利，显示市场对公司基本面有信心，投资者将密切关注财务指标。
11-06 05:24
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Insights Ahead: Simpson Manufacturing Co's Quarterly Earnings
Simpson Manufacturing Co (NYSE:SSD) will release its quarterly earnings report ...
10-25 01:01
Resideo To Participate at Upcoming Investor Conferences
SCOTTSDALE, Ariz., Oct. 22, 2025 /PRNewswire/ -- Resideo Technologies, Inc. (NYSE: REZI), a leading global manufacturer, developer, and distributor of technology-driven sensing and controls ...
10-23 04:05
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations
Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025.
10-14 00:46
